

**Table S4.** Effect of rhIGF-1 therapy on height velocity (cm/year; Registry population)

	Change from baseline				Change from baseline			
	N	Mean (SD)	N	Mean (95% CI)	N	Mean (SD)	N	Mean (95% CI)
	<b>NPP-LS</b> ( <i>n</i> = 21)				<b>NPP-non-LS</b> ( <i>N</i> = 114)			
1 year	10	8.25 (2.54)	4	-	87	7.04 (1.96)	52	2.42 (1.75; 3.10)
2 years	7	6.87 (1.54)	2	-	70	6.13 (1.59)	40	1.76 (1.06; 2.47)
3 years	9	5.35 (1.57)	2	-	58	6.08 (1.82)	34	1.36 (0.44; 2.28)
4 years	7	5.35 (0.94)	1	-	38	5.60 (1.69)	19	0.70 (-0.27; 1.67)
5 years	5	5.45 (1.10)	0	-	21	4.87 (1.84)	10	1.12 (-0.07; 2.32)
	<b>NPP-non-LS–responders</b> ( <i>n</i> = 50)				<b>NPP-non-LS–poor-responders</b> ( <i>n</i> = 38)			
1 year	50	8.06 (1.69)	35	3.02 (2.31; 3.74)	37	5.66 (1.36)	17	1.18 (-0.19; 2.55)
2 years	38	6.18 (1.50)	27	1.49 (0.78; 2.19)	29	6.05 (1.79)	13	2.34 (0.60; 4.08)
3 years	31	5.95 (1.59)	23	0.77 (-0.16; 1.70)	20	6.50 (2.22)	9	2.43 (-0.30; 5.15)
4 years	19	5.56 (1.19)	14	0.46 (-0.45; 1.36)	11	5.37 (1.88)	4	-
5 years	14	5.06 (2.04)	8	1.01 (-0.52; 2.55)	3	4.64 (1.42)	2	-
	<b>Non-NPP-LS</b>				<b>Non-NPP-non-LS</b>			

	(n = 17)				(n = 86)			
1 year	13	5.50 (2.88)	10	0.38 (-1.32; 2.09)	59	6.48 (2.37)	41	1.73 (0.86; 2.59)
2 years	11	4.90 (2.38)	9	0.04 (-1.40; 1.47)	35	6.00 (2.40)	22	0.68 (-0.43; 1.79)
3 years	10	3.42 (3.21)	7	-2.08 (-5.33; 1.17)	25	5.72 (2.17)	13	0.99 (-0.42; 2.41)
4 years	7	4.55 (2.45)	4	-	16	4.77 (2.11)	7	0.18 (-1.70; 2.05)
5 years	3	4.34 (1.07)	2	-	9	4.35 (2.09)	5	-0.65 (-2.90; 1.60)

Mean (SD/95% CI) are not reported if the N is <5. No statistical analysis was conducted for height velocity. Responders were defined as patients with change in height SDS in year 1 of  $\geq 0.3$ . Poor-responders were defined as patients with change in height SDS in year 1 of  $< 0.3$ . CI, confidence interval; N, number of patients with available data at each time point. LS, Laron syndrome; non-NPP, not treatment naïve and/or pubertal; NPP, treatment-naïve and prepubertal; SD, standard deviation; SDS, standard deviation score.